Skip to main content
. 2019 Feb 15;9(1):93–109.

Figure 1.

Figure 1

Anti-ELTD1 Ab treatment is more effective than anti-VEGFR2 Ab treatment in increasing animal survival and decreasing tumor volumes in a G55 human xenograft model. (A) Percent survival curve for IgG- (n = 7), anti-ELTD1- (n = 7), and anti-VEGFR2 Ab (n = 7) treated mice. Anti-ELTD1 Ab treatment significantly increased animal survival (P < 0.01), compared to either IgG-treated or anti-VEGFR2 Ab-treated mice. IgG was a non-specific IgG used as a control. (B) Tumor volumes of treatment groups (mean ± SD). Anti-ELTD1 Ab treatment significantly decreased tumor volumes at 21 days post-tumor detection (P < 0.05), compared to IgG-treated mice. Morphological representative MR images for IgG- (C), anti-ELTD1 Ab- (D) and anti-VEGFR2 Ab-treated (E) mice at 21 days following initial tumor detection.